Seroprevalence of Epstein-Barr virus among hemodialysis patients: post-exposure analysis
DOI:
https://doi.org/10.65327/kidneys.v14i4.559Keywords:
Epstein-Barr virus; infectious mononucleosis; hemodialysis; seroprevalence; enzyme-linked immunosorbent assayAbstract
Background. Epstein-Barr virus (EBV) is a ubiquitous member of the γ-herpesvirus subfamily within the Herpesviridae family and is known to cause infectious mononucleosis. EBV may contribute to morbidity and mortality in hemodialysis patients. Hemodialysis is a procedure used in individuals with end-stage renal failure to remove waste products, salts, and excess fluids from the bloodstream. The aim of this study was to assess EBV IgG antibody infection in patients undergoing hemodialysis. Materials and methods. EBV IgG antibodies were evaluated in 88 blood samples collected from hospitalized hemodialysis patients using enzyme-linked immunosorbent assay. Results. The study included 51 males and 37 females, with an age range from 15 to 75 years, divided into four categories. The mean age was 52.00 ± 16.46 years. EBV seropositivity was found in 36.36 % of patients (23.86 % in males and 12.50 % in females), while 63.64 % tested negative. No statistically significant differences were observed between gender and age groups (P = 0.5). Among seropositive cases, 12.5 % showed co-infection with hepatitis C virus. The correlation was significant at the 0.01 level. Conclusions. A notable prevalence of EBV IgG antibodies was observed among hemodialysis patients. Seropositivity
reached 36.36 %, while 63.64 % of cases were negative. The highest proportion of seropositive individuals was found among elderly patients aged 75 years, accounting for 31.6 %.
Downloads
References
Chabay P, Preciado MV. Epidemiology of Epstein-Barr virusassociated pediatric lymphomas from Argentina. Bol Med Hosp Infant
Mex. 2016;73(1):47-54. doi: 10.1016/j.bmhimx.2015.12.002.
Michallet M, Sobh M, Ranchon F, Leroy S, Barraco F,
et al. Epstein-Barr virus (EBV) reactivation, its treatment with
rituximab and their impact on relapse after allogeneic hematopoietic stem cell transplantation for hematological malignancies. Blood.
;128:3695. doi: 10.1182/blood.v128.22.3695.3695.
Habib M, Buisson M, Lupo J, Agbalika F, Socié G, et al. Lytic
EBV infection investigated by detection of soluble Epstein-Barr virus
ZEBRA in the serum of patients with PTLD. Sci Rep. 2017;7(1):10479.
doi: 10.1038/s41598-017-09798-7.
Wu CC, Fang CY, Cheng YJ, Hsu HY, Chou SP, et al. Inhibition of Epstein-Barr virus reactivation by the flavonoid apigenin. J
Biomed Sci. 2017;24(1):2. doi: 10.1186/s12929-016-0313-9.
Maeda E, Akahane M, Kiryu S, Ka to N, Yoshikawa T, et al.
Spectrum of Epstein-Barr virus-rela ted diseases: a pictorial review.
Jpn J Radiol. 2009;27(1):4-19. doi: 10.1007/s11604-008-0291-2.
Vanichanan J, Udomkarnjananun S, Avihingsanon Y, Jutivorakool K. Common viral infections in kidney transplant recipients. Kidney Res Clin Pract. 2018;37(4):323-337. doi: 10.23876/j.
krcp.18.0063.
De Melo Silva J, Pinheiro-Silva R, Dhyani A, Pontes GS.
Cytomegalovirus and Epstein-Barr infections: prevalence and impact on patients with hematological diseases. Biomed Res Int.
;2020:1627824. doi: 10.1155/2020/1627824.
Randhawa PS, Magnone M, Jordan M, Shapiro R, Demetris AJ,
Nalesnik M. Renal allograft involvement by Epstein-Barr virus-associated post-transplant lymphoproliferative disease. Am J Surg Pathol.
;20(5):563-571. doi: 10.1097/00000478-199605000-00003.
San-Juan R, Comoli P, Caillard S, Moulin B, Hirsch HH,
Meylan P; ESCMID Study Group of Infection in Compromised Hosts.
Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin Microbiol Infect. 2014;20
(Suppl 7):109-118. doi: 10.1111/1469-0691.12534.
Petrara MR, Giunco S, Serraino D, Dolcetti R, De Rossi A.
Post-transplant lymphoproliferative disorders: from epidemiology to
pathogenesis-driven treatment. Cancer Lett. 2015;369(1):37-44. doi:
1016/j.canlet.2015.08.007.
Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, et al. Kidney transplantation as primary therapy for end-stage
renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI) conference. Clin J Am Soc
Nephrol. 2008;3(2):471-480. doi: 10.2215/cjn.05021107.
Ibrahim MN, Alhadi MS, Elbadawy WY, Al-Sharari MS,
Al-Ruwali HM, Al-Anazi TM. Serodetection of cytomegalovirus and
Epstein-Barr virus antibodies among hemodialysis patients. Biomed
Pharmacol J. 2022;15(1):249-254. doi: 10.13005/bpj/2360.
Sitki-Green D, Covington M, Raab-Traub N. Compartmentalization and transmission of multiple Epstein-Barr virus strains in
asymptomatic carriers. J Virol. 2003;77(3):1840-1847. doi: 10.1128/
jvi.77.3.1840-1847.2003.
Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3(5):1526-1533. doi: 10.2215/
cjn.00950208.
Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, et al. The interplay between Epstein-Barr virus and the immune system: arationale for adoptive cell therapy of EBV-related disorders. Haematologica. 2010;95(10):1769-1777. doi: 10.3324/haematol.2010.
Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol. 2010;172(4):363-371.
doi: 10.1093/aje/kwq177.
Green M, Michaels MG. Epstein-Barr virus infection and
posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13
(Suppl 3):41-54. doi: 10.1111/ajt.12004.
Colombini E, Guzzo I, Morolli F, Longo G, Russo C, et al.
Viral load of EBV DNAemia is a predictor of EBV-related posttransplant lymphoproliferative disorders in pediatric renal transplant
recipients. Pediatr Nephrol. 2017;32(8):1433-1442. doi: 10.1007/
s00467-017-3627-2.
Cheng JW, Chen YC, Tian YC, Fang JT, Yang CW. Coinfection of cytomegalovirus and miliary tuberculosis in a post-renal transplant recipient. J Nephrol. 2007;20(1):114-118.
Jain M, Duggal S, Chugh TD. Cytomegalovirus infection
in non-immunosuppressed critically ill patients. J Infect Dev Ctries.
;5(8):571-579. doi: 10.3855/jidc.1487.
Orasch C, Conen A. Severe primary cytomegalovirus infection
in the immunocompetent adult patient: a case series. Scand J Infect
Dis. 2012;44(12):987-991. doi: 10.3109/00365548.2012.697637.
Banas B, Böger CA, Lückhoff G, Krüger B, Barabas S, et al.
Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients. BMC
Immunol. 2017;18(1):15. doi: 10.1186/s12865-017-0194-z.
Al-Azzawy MA, Tawfiq SK, Qader SM. Detection of EBV and
CMV coinfection among patients under hemodialysis. Int J Health Sci.
;6(S2):4456-4463. doi: 10.53730/ijhs.v6ns2.6056.
Vilibić-Čavlek T, Kolarić B, Bogdanić M, Tabain I, Beader N. Herpes group viruses: a seroprevalence study in hemodialysis patients. Acta Clin Croat. 2017;56(2):255-261. doi: 10.20471/
acc.2017.56.02.08.
Deeba E, Koptides D, Gaglia E, Constantinou A, Lambrianides A, et al. Evaluation of Epstein-Barr virus-specific antibodies in
Cypriot multiple sclerosis patients. Mol Immunol. 2019;105:270-275.
doi: 10.1016/j.molimm.2018.12.010.
Saghafi H, Qorashi M, Heidari A. Is screening for IgG antibody to cytomegalovirus and Epstein-Barr virus infections mandatory in potential renal transplant recipients and donors in Iran?
Transplant Proc. 2009;41(7):2761-2763. doi: 10.1016/j.transproceed.2009.07.057.
Hjelmesaeth J, Sagedal S, Hartmann A, Rollag H, Egeland T, et al. Asymptomatic cytomegalovirus infection is associated
with increased risk of new-onset diabetes mellitus and impaired insulin
release after renal transplantation. Diabetologia. 2004;47(9):1550-
doi: 10.1007/s00125-004-1499-z.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mays B. Jalil, Mohammed Younus Naji Al Atbee
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 
ISSN 
